
- /
- Supported exchanges
- / US
- / DSNKY.PINK
Daiichi Sankyo Co Ltd ADR (DSNKY PINK) stock market data APIs
Daiichi Sankyo Co Ltd ADR Financial Data Overview
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications caused by bone metastasis from tumors; Tarlige for treating neuropathic pain; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for COVID-19 infection, influenza infection, adsorbed cell culture-derived influenza (H5N1), measles/rubella infection, and mumps. The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Daiichi Sankyo Co Ltd ADR data using free add-ons & libraries
Get Daiichi Sankyo Co Ltd ADR Fundamental Data
Daiichi Sankyo Co Ltd ADR Fundamental data includes:
- Net Revenue: 1 886 256 M
- EBITDA: 380 573 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Daiichi Sankyo Co Ltd ADR News

AstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung Cancer
AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced that the FDA had granted accelerated approval to Datroway for the treatment ...


Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Merck MRK has built a substantial portfolio of new products and pipeline candidates in areas like oncology, vaccines, neuroscience, and infectious disease. Merck’s phase III pipeline has almost tri...

FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
AstraZeneca AZN announced that the FDA has expanded the label of its cancer drug Datroway for a second indication — non-small cell lung cancer (NSCLC). The drug has been developed in partnership wit...

US approves AstraZeneca, Daiichi's treatment for lung cancer
(Reuters) -AstraZeneca said on Tuesday that U.S. regulators have approved its precision drug Datroway to treat a type of lung cancer, adding that the drugmaker would now pay partner Daiichi Sankyo $45 million in milestone-related considerations. </p>
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.